Last reviewed · How we verify
BTT1023
BTT1023 is a monoclonal antibody that blocks the CC chemokine receptor 2 (CCR2) to reduce inflammatory cell recruitment and immune activation.
BTT1023 is a monoclonal antibody that blocks the CC chemokine receptor 2 (CCR2) to reduce inflammatory cell recruitment and immune activation. Used for Rheumatoid arthritis, Inflammatory bowel disease.
At a glance
| Generic name | BTT1023 |
|---|---|
| Sponsor | Biotie Therapies Corp. |
| Drug class | CCR2 antagonist monoclonal antibody |
| Target | CCR2 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
BTT1023 targets CCR2, a chemokine receptor involved in the recruitment of monocytes and other immune cells to sites of inflammation. By blocking CCR2, the drug aims to reduce inflammatory infiltration and modulate immune responses in inflammatory and autoimmune conditions. This mechanism is intended to decrease pathogenic inflammation while preserving beneficial immune function.
Approved indications
- Rheumatoid arthritis
- Inflammatory bowel disease
Common side effects
- Infection
- Infusion reactions
- Headache
Key clinical trials
- A Trial of BTT1023 in Patients With Primary Sclerosing Cholangitis (PHASE2)
- BTT-1023 in Rheumatoid Arthritis (PHASE1)
- BTT1023 in Psoriasis (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BTT1023 CI brief — competitive landscape report
- BTT1023 updates RSS · CI watch RSS
- Biotie Therapies Corp. portfolio CI